News & Updates

Longer-term follow-up results of the JAVELIN Bladder 100 trial continue to show prolonged overall survival (OS) and progression-free survival (PFS) with avelumab first-line maintenance and best supportive care (BSC) among Asian patients with advanced urothelial carcinoma (UC) compared with BSC alone.

Safety data from the phase III ADAURA study support osimertinib as an effective adjuvant therapy for resectable, stage IB–IIIA EGFR-mutated non–small-cell lung cancer (NSCLC), says an expert.

Treatment with inclisiran in real-world settings appears to produce significant reductions in low-density lipoprotein cholesterol (LDL-C) at 2 months with good tolerability, with results consistent with that reported in previous trials, according to a study.

New drug applications approved by US FDA as of 01 - 15 December 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Lenadogene nolparvovec is well tolerated among patients with Leber hereditary optic neuropathy, being associated with mostly mild ocular side effects that can be resolved with conventional ophthalmologic treatments, according to the results of the LHON study.